

## CASE LA29a DIV-2

During a telephone discussion, the Examiner raised an objection to Claim 34 which involved treating "a premalignant disease". Applicants have deleted "a premalignant disease" from Claim 34 via the above amendment.


It is believed that this application is in good form for examination.

Respectfully submitted,

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
(609) 252-4336


Date:

*March 14, 2003*

  
Burton Rodney  
Attorney for Applicants  
Reg. No. 22,076

MARKED-UP VERSION TO SHOW CHANGES

-34. (Twice Amended) A method for lowering blood glucose levels or for treating diabetes, or for treating [a premalignant disease,] an early malignant disease, a malignant disease or a dysplastic disease, which comprises administering to a patient in need of treatment a therapeutically effective amount of a compound which has the structure



wherein x is 1, 2, 3 or 4; m is 1 or 2; n is 1 or 2;

Q is C or N;

A is O or S;

Z is O or a bond;

R<sup>1</sup> is H or lower alkyl;

X is CH;

R<sup>2</sup> is H, alkyl, alkoxy, halogen, amino or substituted amino;

R<sup>2a</sup>, R<sup>2b</sup> and R<sup>2c</sup> are the same or different and are selected from H, alkyl, alkoxy, halogen, amino or substituted amino;

R<sup>3</sup> is aryloxycarbonyl, alkylloxycarbonyl, alkynylloxycarbonyl, alkenylloxycarbonyl, alkyl(halo)aryloxycarbonyl, alkyl(oxy)(halo)aryloxycarbonyl, cycloalkylaryloxycarbonyl, cycloalkyloxyaryloxycarbonyl, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, alkoxy carbonylamino, aryloxycarbonylamino, heteroaryloxycarbonylamino, alkylsulfonyl, alkenylsulfonyl, heteroaryloxycarbonyl, cycloheteroalkylloxycarbonyl, heteroarylalkenyl, hydroxyalkyl, alkoxy, alkoxyaryloxycarbonyl, arylalkylloxycarbonyl, alkylaryloxycarbonyl, alkynylloxycarbonyl, haloalkoxyaryloxycarbonyl, alkoxy carbonylaryloxycarbonyl, aryloxyaryloxycarbonyl, arylalkenylloxycarbonyl, heteroaryloxyarylalkyl, aryloxyarylalkylloxycarbonyl, aryloxyalkylloxycarbonyl, arylalkylsulfonyl, arylthiocarbonyl, arylalkenylsulfonyl, heteroarylsulfonyl, arylsulfonyl, heteroarylalkoxy carbonyl, heteroarylalkyloxyarylalkyl, arylalkenylarylalkyl, arylalkoxy carbonyl/heteroarylalkyl, heteroaryloxyarylalkyl, arylalkenyl/heteroarylalkyl or polyhaloalkylaryloxycarbonyl;

CASE LA29a DIV-2

Y is  $\text{CO}_2\text{R}^4$  where  $\text{R}^4$  is H or alkyl, or a prodrug ester or Y is a C-linked 1-tetrazole, a phosphinic acid of the structure  $\text{P}(\text{O})(\text{OR}^{4a})\text{R}^5$  here  $\text{R}^{4a}$  is H or a prodrug ester,  $\text{R}^5$  is alkyl or aryl or a phosphonic acid of the structure  $\text{P}(\text{O})(\text{OR}^{4a})_2$  where  $\text{R}^{4a}$  is H or a prodrug ester;

or stereoisomers thereof, a prodrug [esters] ester thereof, and a pharmaceutically acceptable [salts] salt thereof. --